Get started
Keyword

neratinib

Description: An oral, irreversible tyrosine kinase inhibitor that targets HER-family receptors and is used to treat HER2-positive cancers.
Wikidata ID: wiki/Q6995920
OpenAlex ID: keywords/neratinib
HER2-targeted therapies — a role beyond breast cancer
2019 · Do-Youn Oh, Yung-Jue Bang · Nature Reviews Clinical Oncology · 1,074
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
2012 · Ron Bose, Shyam M. Kavuri, et al. · Cancer Discovery · 868
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
2018 · David M. Hyman, Sarina A. Piha-Paul, et al. · Nature · 775
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
2011 · Hiroyuki Yasuda, Susumu Kobayashi, et al. · The Lancet Oncology · 605
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
2020 · Cristina Saura, Mafalda Oliveira, et al. · Journal of Clinical Oncology · 602
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
2017 · Miguel Martin, Frankie A Holmes, et al. · The Lancet Oncology · 587
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
2016 · Arlene Chan, Suzette Delaloge, et al. · The Lancet Oncology · 562
Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
2010 · Harold J. Burstein, Yan Sun, et al. · Journal of Clinical Oncology · 522
PDF
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
2011 · Devika Gajria, Sarat Chandarlapaty · Expert Review of Anticancer Therapy · 494
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial
2020 · Xu, Feng, Awada, Ahmad, et al. · Carolina Digital Repository (University of North Carolina at Chapel Hill) · 482
Adaptive Randomization of Neratinib in Early Breast Cancer
2016 · John W. Park, Minetta C. Liu, et al. · New England Journal of Medicine · 454
PDF
Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
2009 · Kim-Son H. Nguyen, Susumu Kobayashi, et al. · Clinical Lung Cancer · 435
Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer
2010 · Lecia V. Sequist, Benjamin Besse, et al. · Journal of Clinical Oncology · 429
PDF
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
2020 · Nicholas C Turner, Belinda Kingston, et al. · The Lancet Oncology · 369
PDF
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
2019 · Rachel A. Freedman, Rebecca S. Gelman, et al. · Journal of Clinical Oncology · 341
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
2015 · J. Mazières, F. Barlesi, et al. · Annals of Oncology · 325
PDF
The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance
2016 · Susan Breslin, Lorraine O’Driscoll · Oncotarget · 312
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer
2016 · Ahmad Awada, Ramon Colomer, et al. · JAMA Oncology · 305
PDF
A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
2009 · Kwok-K. Wong, Paula M. Fracasso, et al. · Clinical Cancer Research · 301
PDF
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
2015 · Shyam M. Kavuri, Naveen Jain, et al. · Cancer Discovery · 300
PDF
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
2021 · Ilana Schlam, Sandra M. Swain · npj Breast Cancer · 290
PDF
Blood–Brain Barrier in Brain Tumors: Biology and Clinical Relevance
2021 · Francesca Mo, Alessia Pellerino, et al. · International Journal of Molecular Sciences · 245
PDF
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies
2018 · Utthara Nayar, Ofir Cohen, et al. · Nature Genetics · 230
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial
2020 · Arlene Chan, Beverly Moy, et al. · Clinical Breast Cancer · 222
Novel HER2–targeted therapies for HER2–positive metastatic breast cancer
2020 · Siddharth Kunte, Jame Abraham, et al. · Cancer · 214
PDF
Works count: 1,675
Citation count: 29,730
Year
Topic
Type